Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies due to its late diagnosis and limited response to treatment. B6-KPC mice ( LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre) generate spontaneous PDAC which could recapitulate the pathogenesis and genomic features of human PDAC. Although B6-KPC model is a wildly used for the exploration of the mechanisms of PDAC, some drawbacks of the model, such as long time for tumorigenesis, individual variation and difficulties in tumor observation, limit its application in cancer therapy. It is necessary to develop the pancreatic tumor cell lines from these models. In this study, we successfully established and well-characterized the luciferase-labled cell line mPAKPC-Luciferase. This cells carried the KrasG12D and Trp53R172H mutation. The orthotopic mPAKPC-Luciferase tumor model was well established by implanting tumor cell line into pancreas of B6 wild type mice and the tumor growth was traced by in vivo imaging. Moreover, Gemcitabine or combined with CD40 agonist presented significant tumor growth inhibition in B6 bearing mPAKPC-Luciferase orthotopic mouse models. While anti-PD1 or anti-OX40 had no anti-tumor effects in this model accordance with the low T cell infiltration of mPAKPC modle as a "cold" tumor. In addition, the immune profiling of this cell line showed highly expressed of potential therapeutic targets, including Claudin 18.2, CD47, CD73. Thus, mPAKPC-Luciferase cell lines are valuable models for the PDAC preclinical therapies. Citation Format: Fang Zhu, Cunxiang Ju, Hongyan Sun, Weiwei Yu, Chao Ju, Shuai Li, Yunlong Jiang, Dongjing Jia, Steve Smith, Zhiying Li, Jing Zhao, Xiang Gao. Novel orthotopic pancreatic cancer cell lines derived from B6-KPC mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 930.

Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Data from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target

Supplementary Table S4 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Table S1 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Abstract 930: Novel orthotopic pancreatic cancer cell lines derived from B6-KPC mice

Supplementary Table S3 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figure from Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer

Figure S1 from Use of <i>ex</i> <i>vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>her2</i> Mutant Non–Small Cell Lung Cancer

Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

Olive , Cancer of Chemotherapy in a Mouse Model of Pancreatic Inhibition of Hedgehog Signaling Enhances Delivery